Publications by authors named "F Stegelmann"
Measurable residual disease (MRD) monitoring in acute myeloid leukemia (AML) with an FLT3 internal tandem duplication (FLT3-ITDpos) has been hampered by the broad heterogeneity of ITD mutations. Using our recently developed FLT3-ITD paired-end next-generation sequencing (NGS)-based MRD assay (limit of detection 10-4 to 10-5), we evaluated the prognostic impact of MRD at different time points in 157 patients with FLT3-ITDpos AML who were enrolled in the German-Austrian Acute Myeloid Leukemia Study Group 16-10 trial and who were treated with a combination of intensive chemotherapy and midostaurin, followed by midostaurin maintenance. MRD negativity (MRDneg) after 2 cycles of chemotherapy (Cy2), which was observed in 111 of 142 (78%) patients, was predictive of superior 4-year rates of cumulative incidence of relapse (CIR) (4y-CIR; 26% vs 46%; P = .
View Article and Find Full Text PDFArticle Synopsis
- * Research on pediatric CML revealed that about 60% of young patients have germline variants, primarily in genes like ASXL1, NOTCH1, KDM6B, and TET2, while adult patients show fewer such variants.
- * This study suggests that these germline variants may work together with the BCR::ABL1 oncogene to increase the risk of developing CML in children, potentially triggering the disease at an earlier age.
Article Synopsis
- Momelotinib, a newly approved JAK1/2 inhibitor, shows promise in treating myelofibrosis (MF) patients, particularly those with anemia, improving hemoglobin and platelet levels over a median treatment duration of 12 weeks.
- In a study of 60 MF patients, 39% of transfusion-dependent individuals experienced reduced transfusion needs, with 21% achieving transfusion independence in about 4 weeks.
- While momelotinib is effective, it also presented safety concerns, with 17% of patients experiencing creatinine increases, and some patients discontinued treatment due to side effects or worsening symptoms.
Background: Based on the new data from the primary analysis of the OPTIC (Optimizing Ponatinib Treatment in CP-CML) trial on dose optimization of ponatinib in patients with chronic phase (CP)-CML, the German consensus paper on ponatinib published in 2020 (Saussele S et al., Acta Haematol. 2020) has been updated in this addendum.
View Article and Find Full Text PDF